JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Are decreased serum Maresin 1 levels predictive of cholangiocarcinoma?
Abstract
Aims: Cholangiocarcinoma (CC) is a rare form of adenocarcinoma originating from the epithelial cells of the biliary tract. Chronic inflammation is known to be a risk factor for this tumor. The present study aimed to investigate whether serum levels of Maresin 1 (MaR1) (a macrophage-derived anti-inflammatory lipid mediator) were associated with the presence of benign biliary disease (BBD) or CC.
Methods: The study was conducted with 104 participants, including 42 patients with CC, 32 patients with BBD, and 30 volunteers without any hepatobiliary pathology. Blood samples were taken from each participant, and serum MaR1 levels were measured with enzyme-linked immunosorbent assay kits.
Results: Serum MaR1 levels were significantly lower in the CC and BBD groups compared to controls (p < 0.001, for both); however, there was no significant difference between the CC and BBD groups in terms of MaR1 level (p > 0.05). The cancer antigen (CA) 19-9 and carcinoembryonic antigen (CEA) values of the CC group were found to be significantly higher than the BBD and control groups (p < 0.001, for both). Although MaR1 was found to have diagnostic value in differentiating patients with CC or BBD from controls, it had no value in distinguishing CC from BBD; whereas CA19-9 and CEA had significant discriminatory power.
Conclusion: Decreased serum MaR1 level may predict inflammation in hepatobiliary pathologies such as CC and BBD; however, it cannot be used to discriminate CC from BBD, and classical cancer markers such as CA19-9 and CEA appear to retain superiority in this respect.

Keywords : Cholangiocarcinoma, benign biliary disease, Maresin-1

Download Article


1. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-280. doi:10.1038/nrgastro.2016.51
2. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-1279. doi:10.1016/j.jhep.2014.01.021
3. Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65. doi:10.1038/s41572-021-00300-2
4. Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer. Semin Immunol. 2018;40:74-82. doi:10.1016/j.smim.2018.10.011
5. Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009;206(1):15-23. doi:10.1084/jem.20081880
6. Sawada N, Inoue M, Iwasaki M, et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology. 2012;142(7):1468-1475. doi:10.1053/j.gastro.2012.02.018
7. Zhang Q, Zhu B, Li Y. Resolution of cancer-promoting inflammation: a new approach for anticancer therapy. Front Immunol. 2017;8:71. doi:10. 3389/fimmu.2017.00071
8. Liu P, Zhu G, Xia H. Research progress on the role of immune cells regulated by Maresin-1 in inflammatory diseases. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024;36(10):1113-1116. doi:10.3760/cma.j.cn121430- 20240104-00016
9. Han YH, Shin KO, Kim JY, et al. A maresin 1/ROR?/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis. J Clin Invest. 2019;129(4):1684-1698. doi: 10.1172/JCI124219
10. Das UN. Can bioactive lipids augment anti-cancer action of immunotherapy and prevent cytokine storm? Arch Med Res. 2019;50(6): 342-349. doi:10.1016/j.arcmed.2019.10.004
11. Colby JK, Jaoude J, Liu F, Shureiqi I. Oxygenated lipid signaling in tumor-associated macrophages—focus on colon cancer. Cancer Metastasis Rev. 2018;37(2-3):289-315. doi:10.1007/s10555-018-9743-z
12. Buonaguro FM, Tornesello ML, Buonaguro L, et al. Kaposi’s sarcoma: aetiopathogenesis, histology and clinical features. J Eur Acad Dermatol Venereol. 2003;17(2):138-154. doi:10.1046/j.1468-3083.2003.00670.x
13. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303-1314. doi:10.1016/S0140-6736(05)67530-7
14. Sinakos E, Saenger AK, Keach J, et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011;9(5):434-9.e1. doi:10.1016/j.cgh.2011.02.007
15. Samadi A, Sabuncuoglu S, Samadi M, et al. A comprehensive review on oxysterols and related diseases. Curr Med Chem. 2021;28(1):110-136. doi: 10.2174/0929867327666200316142659
16. Arimura K, Aoshiba K, Tsuji T, Tamaoki J. Chronic low-grade systemic inflammation causes DNA damage in the lungs of mice. Lung. 2012;190(6):613-620. doi:10.1007/s00408-012-9414-8
17. Xie Y, Liu F, Wu Y, et al. Inflammation in cancer: therapeutic opportunities from new insights. Mol Cancer. 2025;24(1):51. doi:10. 1186/s12943-025-02243-8
18. Yalcinkaya A, Unal S, Oztas Y. Altered HDL particle in sickle cell disease: decreased cholesterol content is associated with hemolysis, whereas decreased apolipoprotein A1 is linked to inflammation. Lipids Health Dis. 2019;18(1):225. doi:10.1186/s12944-019-1174-5
19. Fernandes Q, Inchakalody VP, Bedhiafi T, et al. Chronic inflammation and cancer: the two sides of a coin. Life Sci. 2024;338:122390. doi:10. 1016/j.lfs.2023.122390
20. Savas Sen Z, Tanir G, Gumuser Cinni R, et al. Multisystem inflammatory syndrome in children during severe acute respiratory syndrome coronavirus-2 pandemic in Turkey: a single-centre experience. J Paediatr Child Health. 2022;58(1):129-135. doi:10.1111/jpc. 15674
21. Panigrahy D, Gilligan MM, Serhan CN, Kashfi K. Resolution of inflammation: an organizing principle in biology and medicine. Pharmacol Ther. 2021;227:107879. doi:10.1016/j.pharmthera.2021.107879
22. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101. doi:10.1038/nature13479
23. Li R, Wang Y, Zhao E, et al. Maresin 1, a proresolving lipid mediator, mitigates carbon tetrachloride-induced liver injury in mice. Oxid Med Cell Longev. 2016;2016:9203716. doi:10.1155/2016/9203716
24. Fang X, Wang H, Ye T, et al. Low serum maresin 1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 2021;20(1):96. doi:10.1186/s12944-021-01518-5
25. Qiu S, Li P, Zhao H, Li X. Maresin 1 alleviates dextran sulfate sodium-induced ulcerative colitis by regulating NRF2 and TLR4/NF-kB signaling pathway. Int Immunopharmacol. 2020;78:106018. doi:10. 1016/j.intimp.2019.106018
26. Vatnick DR, Lehner K, Gilligan M, et al. Control of breast cancer through the resolution of inflammation. FASEB J. 2016;30(S1):698.3.
27. Sheng H, Li P, Chen X, Liu B, Zhu Z, Cao W. Omega-3 PUFAs induce apoptosis of gastric cancer cells via ADORA1. Front Biosci (Landmark Ed). 2014;19(6):854-861. doi:10.2741/4252
28. Varol H, Gül Ö, Ergül B, et al. Relationship between pancreatic cancer and Maresin 1. J Curr Hematol Oncol Res. 2023;1(2):18-23. doi:10.51271/JCHOR-0006
29. Gül-Utku Ö, Karatay E, Ergül B, et al. The role of resolvin D1 in the differential diagnosis of the cholangiocarcinoma and benign biliary diseases. Clin Lab. 2020;66(5):10.7754/Clin.Lab.2020.200212. doi:10. 7754/Clin.Lab.2020.200212
30. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56(1):40-47. doi:10.1067/mge.2002.125105
31. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995;108(3):865-869. doi:10.1016/0016-5085(95)90462-x
Article available in :
Volume 4, Issue 1, 2026
Page : 1-6
https://doi.org/10.51271/JCHOR-0073
Article Information
Received : 16 Nis 2025
Accepted : 04 Eyl 2025
Published : 25 Şub 2026
Corresponding Author :

Salih Karatlı: Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkiye

[email protected]
Citation : Karatlı S, Gül Ö, Kısa Ü, Tekin E, Ergül B. Are decreased serum Maresin 1 levels predictive of cholangiocarcinoma? J Curr Hematol Oncol Res. 2026;4(1):1-6.

Read: 61
Download : 52
Cited: 0
_Footer